Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt to Equity: 2018-2022

Historic Debt to Equity for Theravance Biopharma (TBPH) over the last 3 years, with Jun 2022 value amounting to -$1.13.

  • Theravance Biopharma's Debt to Equity rose 10.96% to -$1.13 in Q2 2022 from the same period last year, while for Jun 2022 it was -$1.13, marking a year-over-year increase of 10.96%. This contributed to the annual value of -$1.15 for FY2021, which is 11.18% up from last year.
  • Theravance Biopharma's Debt to Equity amounted to -$1.13 in Q2 2022, which was down 1.22% from -$1.12 recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Debt to Equity ranged from a high of -$1.02 in Q4 2019 and a low of -$4.45 during Q4 2018.
  • Moreover, its 3-year median value for Debt to Equity was -$1.24 (2021), whereas its average is -$1.39.
  • Per our database at Business Quant, Theravance Biopharma's Debt to Equity skyrocketed by 76.99% in 2019 and then fell by 26.13% in 2020.
  • Theravance Biopharma's Debt to Equity (Quarterly) stood at -$4.45 in 2018, then soared by 76.99% to -$1.02 in 2019, then fell by 26.13% to -$1.29 in 2020, then increased by 11.18% to -$1.15 in 2021, then grew by 10.96% to -$1.13 in 2022.
  • Its Debt to Equity stands at -$1.13 for Q2 2022, versus -$1.12 for Q1 2022 and -$1.15 for Q4 2021.